Suppr超能文献

大鼠垂体中免疫反应性β-内啡肽释放的肾上腺素能控制:体外和体内研究

Adrenergic control of immunoreactive beta-endorphin release from the pituitary of the rat: in vitro and in vivo studies.

作者信息

Pettibone D J, Mueller G P

出版信息

J Pharmacol Exp Ther. 1982 Jul;222(1):103-8.

PMID:6283065
Abstract

The adrenergic control of pituitary beta-endorphin release was investigated by testing the effect of various alpha and beta adrenergic drugs on the secretion beta-endorphin-like immuno-reactivity (beta-END-LI) from primary cell cultures of anterior and neurointermediate lobes as well as into plasma in vivo. Incubation of anterior lobe cells with several adrenergic agonists (10-7-10-5 M) evoked significant release of beta-END-LI with the following potency order; l-epinephrine greater than alpha-methylnorepinephrine greater than guanfacine = methoxamine = l-isoproterenol. The epinephrine- and isoproterenol-induced release from anterior lobes were both inhibited by phenoxybenzamine but not propranolol, suggesting mediation by alpha adrenoceptors. Release of beta-END-LI from cultured neurointermediate lobe cells was also stimulated 3-fold by epinephrine or isoproterenol (10-100 nM) but appeared to do so via a beta adrenergic mechanism because propranolol blocked their effects. Administration of l-epinephrine (100 micrograms/kg s.c.) or l-isoproterenol (200 micrograms/kg s.c.) to rats evoked a 3- to 4-fold increase in plasma beta-END-LI, which peaked 30 min after injection and was dose-dependent up to 500 micrograms/kg, Pretreatment with phenoxybenzamine (5 mg/kg i.p.) 30 min before epinephrine (100 micrograms/kg s.c.) inhibited the drug-induced rise whereas propranolol (2 mg/Kg i.p.) blocked the increase in plasma beta-END-LI after isoproterenol (200 micrograms/kg, s.c.) These results demonstrate that alpha and beta adrenergic stimulation selectively release beta-END-LI from cultured anterior and neurointermediate lobes, respectively. Furthermore, both mechanisms appear to be active in vivo.

摘要

通过测试各种α和β肾上腺素能药物对垂体前叶和神经中间叶原代细胞培养物中β-内啡肽样免疫反应性(β-END-LI)分泌以及体内血浆中分泌的影响,研究了肾上腺素能对垂体β-内啡肽释放的控制。用几种肾上腺素能激动剂(10⁻⁷ - 10⁻⁵M)孵育前叶细胞,可引起β-END-LI的显著释放,其效价顺序如下:l-肾上腺素>α-甲基去甲肾上腺素>胍法辛 = 甲氧明 = l-异丙肾上腺素。苯氧苄胺可抑制肾上腺素和异丙肾上腺素诱导的前叶释放,但普萘洛尔则不能,提示其通过α肾上腺素能受体介导。肾上腺素或异丙肾上腺素(10 - 100 nM)也可使培养的神经中间叶细胞中β-END-LI的释放增加3倍,但似乎是通过β肾上腺素能机制,因为普萘洛尔可阻断其作用。给大鼠皮下注射l-肾上腺素(100微克/千克)或l-异丙肾上腺素(200微克/千克)可使血浆β-END-LI增加3至4倍,注射后30分钟达到峰值,在高达500微克/千克时呈剂量依赖性。在肾上腺素(100微克/千克皮下注射)前30分钟腹腔注射苯氧苄胺(5毫克/千克)可抑制药物诱导的升高,而普萘洛尔(2毫克/千克腹腔注射)可阻断异丙肾上腺素(200微克/千克皮下注射)后血浆β-END-LI的增加。这些结果表明,α和β肾上腺素能刺激分别选择性地从培养的前叶和神经中间叶释放β-END-LI。此外,这两种机制在体内似乎都有活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验